Respiratory News and Research

RSS

ResMed launches S9 sleep apnoea therapy platform in Europe

ResMed, a leading developer, manufacturer, and distributor of sleep and respiratory medical equipment, today introduced its new cutting-edge sleep apnoea therapy platform called the S9 Series in Europe. The S9 Series combines a sleek design with superior functionality and more comfort. Combined climate control and humidification delivers unsurpassed comfort to the patient by controlling both the temperature and humidity that the patient breathes.

From ResMed Corp 22 Feb 2010

The Children's House agrees to provide services for children with asthma

The Justice Department today announced a settlement agreement with The Children's House Inc. of Broadview Heights, Ohio, a suburb of Cleveland, to provide services for children with asthma as required by the Americans with Disabilities Act (ADA).

22 Feb 2010

Quidel acquires Diagnostic Hybrids for $130 million

Quidel Corporation, a leading provider of rapid diagnostic tests, has completed its previously announced acquisition of Diagnostic Hybrids, Inc. for approximately $130 million in cash.

20 Feb 2010

USPTO grants SPO Medical innovative baby heart rate monitoring patent

SPO Medical Inc., a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced it has been granted a new and innovative baby monitoring patent relating to a non-invasive device or system for monitoring and measuring the heart rate of a baby to activate an alarm when the level falls outside a predetermined range.

19 Feb 2010

Sacred Heart Medical Center fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards

On January 29, 2010, Sacred Heart Medical Center was cited and fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards. The Department of Labor and Industries Division of Occupational Safety and Health issued the citation and fine for violation of Center for Disease Control and Occupational Safety and Health Administration guidelines on H1N1 and also for violation of the DOSH Directive on Enforcement Procedures for High or Very High Occupational Exposure Risk to the 2009 H1N1 Influenza.

19 Feb 2010

FDA's proposed label changes for LABA asthma medications: GSK reviews

GlaxoSmithKline is reviewing label changes proposed today by the US Food and Drug Administration (FDA) for asthma medications containing long-acting beta-agonists (LABAs), such as GSK's Advair (salmeterol / fluticasone propionate). GSK and makers of the other affected medicines containing LABAs have 30 days to agree with the proposed changes or state why they are not warranted.

19 Feb 2010

Gentiva Health Services announces fourth-quarter and fiscal year 2009 results

Gentiva Health Services, Inc., a leading provider of home health and hospice services, today reported fourth quarter and full year fiscal 2009 results.

18 Feb 2010

State-of-the-art review of stereological methods for lung morphometry

The ATS and the European Respiratory Society have issued official standards for the quantitative assessment of lung structure.

18 Feb 2010

Taking zinc supplements reduces otitis media in healthy children: No clear evidence

A new Cochrane review did not find clear evidence that taking zinc supplements reduces the occurrence of middle ear infections or otitis media in healthy children.

18 Feb 2010

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.

18 Feb 2010

Bedford Laboratories launches Indomethacin for Injection

Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., a provider of select specialty injectables, is pleased to announce the addition of Indomethacin for Injection to its existing product line. This product is AP rated and is equivalent to Indocin® by Lundbeck, Inc. Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.

17 Feb 2010

CMAJ study: Increased dosage of Tamiflu required in treating H1N1 influenza patients

An increased dosage of Tamiflu (oseltamivir) for patients with critical illness is unlikely to be required in the treatment of pandemic (H1N1) influenza, contrary to current international guidelines, found a new study http://www.cmaj.ca/cgi/doi/10.1503/cmaj.092127 in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

17 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

Teva Pharmaceutical Industries announces fourth-quarter and full-year 2009 financial results

Teva Pharmaceutical Industries Ltd. today reported record results for the quarter and year ended December 31, 2009.

16 Feb 2010

NorTech announces winners of annual Innovation Awards program

NorTech, in partnership with Crain's Cleveland Business, is pleased to announce the winners of its annual Innovation Awards program which honors the achievements of Northeast Ohio's most innovative organizations and leaders.

16 Feb 2010

Hypnosis has potential therapeutic value in children with respiratory disorders

Hypnosis has potential therapeutic value in children with respiratory disorders for alleviating symptoms such as habit cough or unexplained sensations of difficulty breathing and for lessening a child's discomfort during medical procedures.

15 Feb 2010

U.S. Court rules in favor of Perrigo over Mucinex patent litigation

Perrigo Company announced today that a federal court has granted summary judgment in its favor in patent litigation involving Guaifenesin Extended-Release Tablets, 600 mg, a generic version of Mucinex® tablets. Perrigo had been sued by Adams Respiratory Therapeutics, Inc., (a subsidiary of Reckitt Benckiser Group plc.) the New Drug Application holder and patent owner. The United States District Court for the Western District of Michigan ruled today that Perrigo does not infringe the patent in the suit. Perrigo's ANDA is awaiting FDA approval.

12 Feb 2010

New amplitude gating technique helps scanners pinpoint tumors

When one diagnoses a cancer patient, it's important to gather as much information about that person as possible. But who would have thought an accurate diagnosis would depend on throwing some of that information away?

12 Feb 2010

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

QIAGEN N.V. and Celera Corporation today announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens.

From QIAGEN Manchester Limited 11 Feb 2010

PAREXEL International, Proteome Sciences form biomarker alliance

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and Proteome Sciences plc, a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of an alliance focused on enhancing PAREXEL's biomarker capabilities for early phase clinical development. PAREXEL is using Proteome Sciences' PS Biomarker Services™ protein and peptide biomarker capabilities to support biopharmaceutical companies in making earlier assessments of new compounds in development.

From Parexel 11 Feb 2010